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ABSTRACT
GCs are highly effective in treating a wide range of in-
flammatory diseases but are limited in their ability to
control neutrophilic lung inflammation in conditions such
as COPD. Neutrophil apoptosis, a central feature of in-
flammation resolution, is delayed in response to mi-
croenvironmental cues, such as hypoxia and inflamma-
tory cytokines, present at inflamed sites. GCs delay
neutrophil apoptosis in vitro, and this may therefore
limit the ability of GCs to control neutrophilic inflamma-
tion. This study assesses the effect GCs have on hyp-
oxia- and inflammatory cytokine-induced neutrophil sur-
vival. Human neutrophils were treated with GCs in the
presence or absence of GM-CSF or inflammatory mac-
rophage-CM at a range of oxygen concentrations
(21–1% oxygen). Neutrophil apoptosis and survival were
assessed by flow cytometry and morphological analysis
and neutrophil function, by stimulus-induced shape
change and respiratory burst. Dexamethasone pro-
moted neutrophil survival at 21%, 10%, and 5% oxygen
but not at 1% oxygen. Interestingly, GM-CSF and inflam-
matory CM increased neutrophil survival significantly,
even at 1% oxygen, with cells remaining functionally ac-
tive at 96 h. Dexamethasone was able to reduce the
prosurvival effect of GM-CSF and inflammatory CM in a
hypoxic environment. In conclusion, we found that GCs
do not augment neutrophil survival in the presence of
severe hypoxia or proinflammatory mediators. This
suggests that GCs would not promote neutrophil sur-
vival at sites of inflammation under these conditions.
J. Leukoc. Biol. 94: 1285–1292; 2013.
Introduction
GCs are used extensively and are highly effective in a wide range
of inflammatory conditions, including polymyalgia rheumatica,
ulcerative colitis, and asthma. However, neutrophilic inflamma-
tion, such as that seen in COPD and emphysema, is relatively GC-
resistant, although the reasons for this remain unclear.
As key effector cells of the innate inflammatory response,
neutrophils migrate rapidly to the site of tissue injury to con-
tain and clear the initiating noxious stimulus. Timely resolu-
tion of this proinflammatory response is crucial for the resto-
ration of tissue homeostasis, with neutrophil apoptosis and
subsequent nonphlogistic removal by surrounding phagocytes
central to this resolution process. In the circulation, neutro-
phils appear to have a relatively short lifespan of only a few
hours [1, 2]. However, at an inflammatory site, neutrophil sur-
vival increases to several days, as a result of delayed apoptosis
induced by environmental factors, such as hypoxia, pyrexia,
and low pH, as well as proinflammatory mediators, including
bacterial products, such as LPS and cytokines, including GM-
CSF and TNF- [3–6]. These serve to increase the expression
of several survival proteins, such as the Bcl-2 family member
Mcl-1, resulting in reduced downstream caspase activation [2,
7–12]. This increase in longevity provides neutrophils with an
appropriate time-frame in which to perform their inflamma-
tory functions (including phagocytosis, degranulation, and
ROS production) and for the recruitment of macrophages for
subsequent phagocytosis of effete and apoptotic neutrophils
[13]. However, an inappropriate delay in neutrophil apoptosis
can propagate the proinflammatory response with increased
release of histotoxic mediators, resulting in local tissue dam-
age [13, 14].
GCs modulate the inflammatory response through a variety
of mechanisms, including alteration of cytokine production,
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increased macrophage phagocytic capacity, transactivation of
anti-inflammatory genes, and transrepression of key proinflam-
matory transcription factors [15]. GCs are, however, powerful
inducers of neutrophil survival in standard laboratory condi-
tions in vitro [16] through a poorly described mechanism in-
volving PI3K signaling and subsequent up-regulation of Mcl-1
[12]. Along with increasing recruitment from bone marrow
and marginated neutrophil pools, this delay in apoptosis has
been suggested as an important factor in GC-induced periph-
eral blood neutrophilia and their relative ineffectiveness in
controlling lung neutrophilic inflammation [17–19].
Physiological oxygen levels vary between 5–11% in the circu-
lation and 3–5% in normal tissue [20]. However, in inflamed
tissues, oxygen levels fall below 2%, as a result of a disrupted
blood supply and increased cellular metabolic activity and with
regards to the normal tissue oxygenation cited above, are re-
garded as hypoxic [20–22]. The change in oxygen tension
that occurs as neutrophils migrate into an area of inflamma-
tion is a major factor in their survival [6]. Primarily, this is
through HIF-1-NF-B-dependent mechanisms involving prolyl
hydroxylase 3, resulting in a variety of effects, including the
induction of Mcl-1 expression [8, 9, 23].
Within an inflammatory and hypoxic environment, there is
little evidence regarding the effect of GCs on neutrophil sur-
vival, particularly, as hypoxia may alter GC function in other
cells, including macrophages and lung epithelial cells [24].
Our study therefore aimed to assess the impact of GCs on neu-
trophil survival in a variety of oxygen tensions, along with con-
comitant exposure to inflammatory mediators. We investigated
whether GCs could augment neutrophil survival during hyp-
oxia in the presence or absence of other proinflammatory fac-
tors.
MATERIALS AND METHODS
Isolation of primary human neutrophils and
monocytes
Neutrophils and PBMCs were isolated from the peripheral blood of healthy
human volunteers using a discontinuous Percoll gradient as described [3,
25, 26]. Monocytes were subsequently purified from PBMCs by negative
selection with magnetic beads (Miltenyi Biotec, Surrey, UK), according to
the manufacturer’s instructions. Neutrophil and monocyte purity was
96%, as assessed by analysis of cytocentrifuge preparations and flow cy-
tometry. Ethical approval was obtained from the Lothian Research Ethics
Committee (08/S1103/38).
Monocyte differentiation and generation of CM
Purified monocytes were differentiated into MDMs by culture in 96-well
plates at 1.5  105 cells/well in 200 l phenol red-free IMDM (Invitrogen,
Paisley, UK) with 10% autologous serum [27]. The monocytes were cul-
tured for 5 days with the media changed on Day 3. CM was generated by
stimulating MDMs with 1 ng/ml LPS (Sigma-Aldrich, Dorset, UK) for 20 h.
The resulting supernatant was removed and frozen at 20°C until use.
Neutrophil treatments
Purified neutrophils were cultured in 96-well plates at 7.5  105 cells/well
in 150 l phenol red-free IMDM (Invitrogen) with 10% autologus serum at
various oxygen concentrations (1%, 5%, 10%, and 21%) using a Bio-
Spherix OxyCycler C42 dual chamber (Wolf Laboratories, York, UK).
Other standard culture parameters (5% CO2, 37°C with humidity) were
maintained at all oxygen levels. Neutrophils were treated with or without
GM-CSF (R&D Systems, Abingdon, UK), dexamethasone (Sigma-Aldrich),
LY294002 (Merck Serono, Middlesex, UK), Akt inhibitor IV (Merck Se-
rono), and CM at the concentrations and time-scales detailed in the indi-
vidual figure legends.
Assessment of neutrophil survival, apoptosis, and
necrosis
Neutrophil viability, apoptosis, and necrosis were measured by flow cytom-
etry with Alexa Fluor 647-labeled AnnV (Cambridge Biosciences, Cam-
bridge, UK) and PI (Sigma-Aldrich) or by hypodiploid DNA peak assay, as
described [28], with results confirmed by morphological assessment of Diff-
Quick-stained cytocentrifuge preparations (IBG Immucor, West Sussex,
UK). Viable cells were defined as AnnV/PI-negative, apoptotic cells AnnV-
positive/PI-negative, and necrotic cells PI-positive. Flow cytometry was per-
formed on a FACSCalibur (BD Biosciences, Oxford, UK) with data ana-
lyzed using on FlowJo (TreeStar, Ashland, OR, USA).
Protein extraction and immunoblotting
Cell lysis was performed using a whole-cell lysis buffer, as described previ-
ously [5]. Protein concentrations were then determined by BCA assay using
the manufacturer’s instructions (Pierce, Thermo Fisher Scientific, Rock-
ford, IL, USA). Immunoblotting was performed using equal amounts of
protein denatured by SDS loading buffer (Invitrogen) and loaded onto
4–12% Bis-Tris gels (Invitrogen), which were transferred to Protran nitro-
cellulose (Whatman, GE Life Sciences, UK) and detection performed using
ECL Prime (GE Life Sciences). Antibodies included anti-NF-B, anti-Mcl-1,
and anti-GR (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-
actin (Sigma-Aldrich).
Assessment of neutrophil activation
Neutrophils cultured in 96-well plates at 7.5  105/well with 20 ng/ml
GM-CSF for 96 h at 1% oxygen were stained with AnnV and PI. Viable
cells (AnnVve/PIve) were purified by cell sorting (FACSAria II cell
sorter; BD Biosciences). More than 96% of sorted neutrophils were via-
ble, as determined by AnnV/PI staining, hypodiploid DNA peak, and
morphological analysis of cytocentrifuge preparations. Neutrophil activa-
tion was assessed by fMLF-induced respiratory burst and shape change.
Superoxide anion generation was estimated as an increase in reactive
oxygen intermediates, indicated by oxidation of the nonfluorescent
DHR (Invitrogen) to the fluorescent rhodamine123. Briefly, neutrophils
(2106/ml) incubated with DHR (1M) for 5 min at 37°C. Cells were
then stimulated with fMLF (100 nM) for 15 min and placed on ice. The
change in fluorescence and forward-scatter was measured by flow cytom-
etry to determine superoxide anion generation and shape change, re-
spectively.
Statistical analysis
Data are presented as mean  sem. Statistical analysis was performed using
ANOVA with a Tukey’s post hoc test, and P  0.05 was considered signifi-
cant. Data analyses were performed using GraphPad Prism software (La
Jolla, CA, USA).
RESULTS
GCs promote neutrophil survival at 21% oxygen
A number of GCs used in clinical practice, including the arche-
typal GC dexamethasone (Fig. 1A and B) as well as budesonide
(Fig. 1C), beclamethasone (Fig. 1D), and 6-methylprednisolone
(Fig. 1E) all promote neutrophil survival in a concentration-
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dependent manner by delaying neutrophil apoptosis under stan-
dard culture conditions (21% oxygen). The promotion of neutro-
phil survival (AnnV and PI-negative cells) by dexamethasone is
time-dependent, as it diminishes over time from 60% survival at
24 h to 30% survival at 48 h, although this is still significantly
greater than untreated cells at 48 h (Fig. 1F). By 72 h, however,
the survival effect of dexamethasone is lost, with 10% survival in
dexamethasone-treated and in untreated control cells (Fig. 1F).
During the first 24 h, cell death occurs predominantly through
apoptosis (Fig. 1G) with subsequent secondary necrosis evident at
later time-points (Fig. 1H).
GC-mediated neutrophil survival is P13K-dependent
and is lost under hypoxia
In keeping with previous data [7], we demonstrate that in-
creasing levels of hypoxia promotes neutrophil survival at 24 h
in a concentration-dependent manner (Fig. 2A). Furthermore,
hypoxia-mediated neutrophil survival (at 1% oxygen) is inde-
Figure 1. GCs increase neutrophil survival by de-
laying apoptosis under standard culture condi-
tions (21% oxygen). (A) Representative cytocen-
trifuge images showing neutrophil morphology
and AnnV/PI binding of neutrophils that have
been freshly isolated or cultured for 24 h, with
or without 100 nM dexamethasone (Dex). (B–E)
Concentration responses (1 nM–10 M) of (B)
dexamethasone, (C) budesonide, (D) beclomethasone, and (E) 6-methylprednisolone on neutrophil apoptosis. (F–H) Percentage of neutrophil
(F) survival, (G) apoptosis, and (H) necrosis over a time-course of 72 h in standard culture conditions (21% oxygen), as assessed by flow cytom-
etry of AnnV/PI binding. Open bars represent cells cultured without dexamethasone; closed bars represent cells cultured with 100 nM dexameth-
asone. Data are shown as mean  sem; n  6–9; *P  0.05; ***P  0.001.
Marwick et al. Hypoxia limits steroid-induced neutrophil survival
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pendent of the prosurvival PI3K/Akt signaling pathway,
whereas GC-mediated survival (at 21% oxygen) is PI3K/Akt-
dependent (Fig. 2B and C). Dexamethasone promotes neutro-
phil survival at 24 h at 21%, 10%, and 5% oxygen (Fig. 2A).
At 1% oxygen, however, dexamethasone causes no further in-
crease in neutrophil survival (Fig. 2A).
Both dexamethasone and hypoxia induce the expression of
NF-B, as well as the prosurvival factor Mcl-1 (Fig. 2C). Hyp-
oxia also increased the expression of the GR (Fig. 2D). In-
deed, there was no change in the expression of NF-B or
Mcl-1 with dexamethasone treatment under hypoxia (Fig. 2C).
Consistent with this, dexamethasone does not alter the rate of
neutrophil apoptosis over 96 h at 1% oxygen (Fig. 3A).
GM-CSF-mediated neutrophil survival is reduced by
GCs only in hypoxic conditions
GM-CSF is a powerful neutrophil prosurvival factor. In contrast
to dexamethasone, GM-CSF increases neutrophil survival sig-
nificantly throughout 96 h incubation at 1% oxygen (Fig. 3A).
By 96 h, there is 50% neutrophil survival compared with
10% in control or dexamethasone-treated cells (Fig. 3A).
Importantly, these cells remain functionally active, with fMLF
inducing shape change and oxidative burst (Fig. 3C). Dexa-
methasone has little effect on the prosurvival effects of
GM-CSF at 21% or 5% oxygen (Fig. 4A and B), although it
transiently increases survival at 21% oxygen (Fig. 4A). Interest-
ingly, dexamethasone reduces significantly the GM-CSF-medi-
ated increase in neutrophil survival from 48 h onward when
cultured at 1% oxygen (Fig. 4C and D).
Hypoxia-mediated neutrophil survival is propagated
by inflammatory CM that GCs can impair
Inflammatory CM generated from LPS-treated MDMs increases
neutrophil survival significantly, irrespective of oxygen concen-
tration (Fig. 5A and B). Under standard culture conditions
with 21% oxygen, dexamethasone does not alter CM-induced
survival at 24 h or 48 h but causes a small, yet significant re-
duction in neutrophil survival at 72 h (Fig. 5A). Hypoxia and
CM have an additive effect on the neutrophil lifespan induc-
ing a significant and prolonged increase in survival (Fig. 5B).
Dexamethasone has no effect on CM-mediated survival at 1%
oxygen prior to 96 h but induces a significant reduction in
neutrophil survival at this time-point (Fig. 5A). Importantly,
whereas high concentrations of LPS (100 ng/ml) promote
neutrophil survival [29], the 1-ng/ml used to stimulate the
MDMs had no direct effect on neutrophil survival (Fig. 5C).
DISCUSSION
Here, we show that proinflammatory mediators, but not GCs,
promote neutrophil survival in hypoxic conditions that would
likely be found in inflamed tissues. Conversely, although GCs
inhibit neutrophil survival at 21% oxygen, they are unable to
promote neutrophil apoptosis in inflammatory environments
in vitro.
The timing and manner of neutrophil cell death are funda-
mental for the controlled resolution of an innate inflammatory
response [14]. In standard in vitro conditions (21% oxygen),
GCs increase neutrophil survival by inhibition of apoptosis. In
humans, GCs cause peripheral blood neutrophilia, and their
Figure 2. Neutrophil survival induced by dexamethasone and low oxygen levels is regulated by NF-B and Mcl-1. (A) Percentage of neutrophil
survival at 24 h while cultured at various oxygen levels, with (closed bars) and without (open bars) 100 nM dexamethasone. (B) The impact of a
selective PI3K inhibitor (10 M LY294002) and a selective Akt inhibitor (10 M Akt inhibitor V) on neutrophil survival after 24 h of culture un-
der standard culture conditions (21% oxygen) with 100 nM dexamethasone (closed bars) or at 1% oxygen (open bars). (C) Representative immu-
noblots of the expression of NF-B (p65; 65kDa) and Mcl-1 (40 kDa) induced by dexamethasone (Dex) and hypoxia. (D) Representative immuno-
blot of the expression of GR (GR; 94 kDa) during hypoxia. -Actin (42 kDa) expression shows equal protein loading. Data represent
n  3–8 and are shown as mean  sem; *P  0.05; **P  0.01; ***P  0.001; #P  0.05; ###P  0.001 (compared with 21% oxygen); §P  0.05
(compared with 21% oxygen). PI3Ki, PI3K inhibitor; Akti, Akt inhibitor; Cont, Control.
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ability to promote neutrophil survival has been suggested as a
reason for the relatively limited efficacy of GCs in lung neutro-
philic inflammation seen in diseases such as COPD [16, 18,
19]. This is in contrast to eosinophil-predominate diseases
(such as asthma), where GCs are a highly effective therapy, in
part, through their ability to induce rapid eosinophil apoptosis
[30]. Therefore, the understanding of why GCs delay neutro-
phil apoptosis may allow the development of more effective
anti-inflammatory drugs for GCunresponsive neutrophilic in-
flammation.
Here, we have shown that dexamethasone is able to mediate
an additional neutrophil prosurvival effect at 10% and 5% oxy-
gen levels at 24 h, suggesting that GCs may be able to pro-
mote neutrophil survival at the higher oxygen levels found in
the circulation, thus potentially contributing to GC-induced
neutrophilia [1]. Although we have also confirmed that reduc-
tion in oxygen tension induces neutrophil survival in a con-
centration-dependent fashion, the ability of GCs to induce an
additional neutrophil prosurvival effect is lost at 1% oxygen.
This is despite hypoxia and GCs eliciting neutrophil survival
through distinct signaling pathways, as illustrated by the in-
volvement of PI3K/Akt signaling in the GC but not the hypox-
ic-mediated survival effect [7, 9]. However, GC and hypoxia
increased the expression of NF-B, the major mediator of hyp-
oxia-HIF-1 in neutrophils [9], and consistent with the litera-
ture, the expression of the NF-B regulated prosurvival factor
Mcl-1 [8, 31]. Therefore, their respective signaling pathways
may eventually converge on a common mechanism that could
explain the lack of an additive effect. Hypoxia itself increased
the expression of the GR, but this increase in expression did
not translate into an increase in GC-mediated survival. This
observation suggests that although GCs may promote neu-
trophil survival in the circulation, they are not likely to aug-
ment the hypoxia-mediated delay in apoptosis at an in-
flamed site where severe hypoxia may occur. An assessment
of neutrophil apoptosis after dexamethasone treatment at
the site of inflammation in vivo would be required to con-
firm this observation.
The observed GC-mediated neutrophil survival at 21% oxy-
gen is, however, time-dependent, being maximal at 24 h, di-
minishing by 50% at 48 h, and lost by 72 h. A similar time-
dependent pattern is also observed from the initial induction
of survival, mediated by hypoxia alone or with GM-CSF alone.
This suggests that a single survival signal alone is adequate to
induce the prolonged neutrophil survival that is seen at an
inflammatory site. Both GM-CSF and the CM containing the
Figure 3. Neutrophil survival medi-
ated by low oxygen levels, GCs, and
GM-CSF. (A) Percentage of neutro-
phil survival when cultured at 1% oxy-
gen at 24 h (closed bars), 48 h (open
bars), 72 h (cross-hatched bars), and
96 h (dotted bars) and cultured with
or without 100 nM dexamethasone or
20 ng/ml GM-CSF. (B) Representative
cytocentrifuge images, flow cytometry
plots of AnnV/PI binding, and DNA
integrity of 96-h GM-CSF-treated neu-
trophils, pre- and postcell sorting for
viable cells (AnnV/PI-negative). (C)
Representative histograms of aged,
GM-CSF-treated, viable neutrophil re-
sponse to fMLF (100 nM) with oxida-
tive burst measured by the oxidation
of DHR to rhodamine 123 and shape
change assessed by change in forward-
scatter. Data represent n  6 and are
shown as mean  sem. ***P  0.001.
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www.jleukbio.org Volume 94, December 2013 Journal of Leukocyte Biology 1289
inflammatory milieu from LPS-stimulated MDMs promote neu-
trophil survival. Similar to GCs and hypoxia, the neutrophil
survival mediated by GM-CSF or CM alone was not sustained
and diminished over time. However, unlike GCs, the increase
in neutrophil survival mediated by GM-CSF and CM was in-
creased at 1% oxygen, resulting in a significant reduction in
the rate of neutrophil death over time. This prolongation of
neutrophil survival with combinations of prosurvival factors is
likely to represent multiple points of control. This ensures that
no one signal can affect neutrophil survival inappropriately,
thus permitting neutrophils to carry out their inflammatory
functions on an appropriate time-scale.
Interestingly, although dexamethasone had little effect on
neutrophil survival mediated by GM-CSF at 21% oxygen, un-
der hypoxic conditions (1% oxygen), dexamethasone reduced
GM-CSF-mediated survival significantly from 48 h onward. Sim-
ilarly, dexamethasone was able to attenuate the neutrophil sur-
vival induced by CM under hypoxia (1% oxygen) at later time-
points (72 h). Therefore, although GCs exert a prosurvival ef-
fect on resting neutrophils at 21% oxygen, this effect is
ameliorated (in the case of hypoxia alone) or reversed by the
presence of an inflammatory environment. The finding that
GCs can be prosurvival or proapoptotic, depending on the
time-scale and microenvironment, is similar to findings with
TNF- that can promote neutrophil survival or apoptosis, de-
pending on the time-scale of exposure and the state of NF-B
activation [5, 32]. Therefore, GCs may only exert a proapop-
totic effect, with combinations of hypoxia and inflammatory
mediators seen at sites of neutrophilic inflammation. Again, an
assessment of neutrophil apoptosis after dexamethasone treat-
Figure 4. GCs attenuate GM-CSF-mediated neutrophil survival in hypoxic conditions. (A–C) The percentage of neutrophil survival when cultured
with GM-CSF (20 ng/ml), with or without dexamethasone (100 nM) at (A) 21% oxygen, (B) 5% oxygen, or (C) 1% oxygen over a 96-h time-pe-
riod; 24 h (closed bars), 48 h (open bars), 72 h (cross-hatched bars), and 96 h (dotted bars). Neutrophil survival in untreated cells under 1% oxy-
gen levels over the 24-, 48-, 72-, and 96-h time-points are 69.4%, 31.1%, 17.4%, and 8.8%, respectively (data not shown). (D) Representative flow
cytometry plots of AnnV/PI binding at 24 h, 48 h, 72 h, and 96 h in culture with GM-CSF (20 ng/ml), with or without dexamethasone (100 nM)
at 1% oxygen. Data represent n  6 and are shown as mean  sem. *P  0.05; **P  0.01.
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ment at sites of inflammation in vivo would be required to
confirm this observation.
In summary, our data show that the promotion of neutro-
phil survival by GCs is lost in the severe hypoxia found within
inflamed tissues. Inflammatory mediators but not GCs prolong
survival during hypoxia. In fact, GCs inhibit proinflammatory,
mediator-induced neutrophil survival at low oxygen levels.
These data suggest that the relative ineffectiveness of GC to
control lung neutrophilic inflammation is not a result of a GC-
dependent promotion of neutrophil survival at sites of inflam-
mation.
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